Validation of Cured Heart Failure Biomarkers | HMC000044 | proteomics, microarrays, biomarkers, heart failure, diagnosis, heart function recovery | 39 | heart disease, end-stage organ failure, heart transplant | Stable Heart Function, Unstable Heart Function | Plasma, Serum, Whole Blood | Proteomics, Transcriptomics | Expression Profiling by Array (Affymetrix HG U133 plus 2), Multiple Reaction Monitoring (MRM) with Mass Spectrometry (MS) | Canadian Institutes of Health Research (CIHR), PROOF Centre of Excellence |
Better Biomarkers For Transplantation | HMC000048 | cardiac transplant, renal transplant, liver transplant, acute rejection, chronic rejection, diagnostic, prognostic, biomarkers | 767 | heart transplant, kidney transplant, liver transplant, end-stage organ failure | Solid organ transplant recipients | Buffy Coat, Heart biopsy, Kidney biopsy, Liver biopsy, Plasma, Serum, Urine, Whole Blood | Metabolomics, Proteomics, Transcriptomics | Expression Profiling by Array (Affymetrix HG U133 plus 2), Expression profiling by array (Affymetrix HU Gene 1.1 ST), Isobaric tag for relative and absolute quantitation (iTRAQ), Multiple Reaction Monitoring (MRM) with Mass Spectrometry (MS), Nuclear Magnetic Resonance spectroscopy (NMR) | Genome British Columbia, St. Paul's Hospital Foundation, Astellas, IBM, Novartis Pharma, Genome Canada |
Diagnostic Biomarkers for Improved Heart Failure Management | HMC000050 | proteomics, transciptiomics, diastolic heart failure, systolic heart failure, preserved ejection fraction, reduced ejection fraction, biomarkers | 261 | diastolic heart failure, systolic heart failure | Heart Failure, Controls | Buffy Coat, Plasma, Serum, Urine, Whole Blood | Proteomics, Transcriptomics | Expression profiling by array (Affymetrix HU Gene 1.1 ST), Multiple Reaction Monitoring (MRM) with Mass Spectrometry (MS) | Mitacs, PROOF Centre of Excellence |
Biomarker Discovery in Acute Heart Failure | HMC000051 | proteomics, transciptiomics, acute heart failure, biomarkers, mechanical circulatory support, ventricular assist device | 13 | acute heart failure | Acute heart failure | Buffy Coat, Plasma, Serum, Urine, Whole Blood | Proteomics | Multiple Reaction Monitoring (MRM) with Mass Spectrometry (MS) | PROOF Centre of Excellence |
Clinical Implementation of Diagnostic Biomarker Assays in Heart and Kidney Transplantation | HMC000052 | heart transplantation, kidney transplantation, proteomics, transcriptomics, acute rejection, diagnosis, prognosis, biomarkers | 692 | heart transplant, kidney transplant, end-stage organ failure | Organ transplant recipients, Non-transplant controls | Buffy Coat, Heart biopsy, Plasma, Serum, Whole Blood | Proteomics, Transcriptomics | Expression Profiling by Array (Affymetrix HG U133 plus 2), Expression profiling by array (Affymetrix HU Gene 1.1 ST), Multiple Reaction Monitoring (MRM) with Mass Spectrometry (MS) | Genome British Columbia, Canada Foundation for Innovation, PROOF Centre of Excellence, Mitacs, Genome Canada |
The Pathognomonic FOXL2 C134W Mutation Alters DNA-Binding Specificity | HMC000065 | FOXL2 transcription factor, adult-type granulosa cell tumors, ovary, cancer, epigenomics | 1 | cancer, granulosa cell tumor | SVOG3e cell line, KGN cell line | Ovary | Epigenomics, Genomics, Proteomics, Transcriptomics | ChIP-seq for H3K27ac (histone modification), ChIP-seq for H3K27me3 (histone modification), ChIP-seq for H3K4me1 (histone modification), ChIP-seq for H3K4me3 (histone modification), Multiple Reaction Monitoring (MRM) with Mass Spectrometry (MS), RNA-seq, Transcription Factor ChIP-seq | Terry Fox Research Institute |
Dysferlinopathy | HMC000086 | limb-girdle muscular dystrophy 2B, LGMD2b, limb girdle muscular dystrophy type R2, LGMDR2, Miyoshi Myopathy type 1, MMD1, dysferlinopathy | 75 | autosomal recessive limb-girdle muscular dystrophy type 2B, dysferlinopathy, limb-girdle muscular dystrophy | Limb-girdle muscular dystrophy 2B, Validation cohort from COS study, healthy age-matched controls | Plasma, Whole Blood | Proteomics, Transcriptomics | Affymetrix GeneChip miRNA 3.1, Expression Profiling by Array (Affymetrix HG U133 plus 2), Isobaric tag for relative and absolute quantitation (iTRAQ) | Jain Foundation |
BQC19: Biobanque québécoise de la COVID-19 | HMC000096 | COVID-19, biobank, multiomics, longitudinal study | 6272 | COVID-19, severe COVID-19, non-severe COVID-19, long COVID, critical COVID-19 | SARS-CoV-2 Positive patients, Mother and Child Centre, SARS-CoV-2 Negative patients | DNA, PBMC, Plasma, RNA, SARS-CoV-2 viral DNA, Serum | Genomics, Metabolomics, Proteomics, Transcriptomics | Genome-Wide Association Study (GWAS), Metabolon, Neutralizing antibodies against SARS-CoV-2, OLINK, RNA-seq, Roche Diagnostics, SARS-CoV-2 specific antibodies detected by ELISA, SomaLogic, Whole Genome Sequencing (WGS) | FRQS (Fonds de Recherche du Quebec-Sante), Quebec's Ministry of Health and Social Services, Public Health Agency of Canada, Genome Quebec |
Mining The Infant Gut Microbiota To Predict And Prevent Asthma: Data From The CHILD Cohort Study | HMC000097 | | 3621 | childhood-onset asthma | Definite Asthma, No Asthma, Possible Asthma | Breast Milk, Cord Blood, Cord blood mononuclear cells (CBMC), DNA, Dust, PBMC, Plasma, RNA, Saliva/Buccal swabs, Serum, Stool, Swab (nasal), Urine, Whole Blood | Epigenomics, Genomics, Hormones, Lipidomics, Metabolomics, Microbiomics, Proteomics | Amplicon Sequencing (16S), Amplicon Sequencing (ITS), DNA Methylation: Infinium Methylation EPIC array, Gas liquid chromatography, Genotyping data using the HumanCoreExome BeadChip (Illumina), High performance liquid chromatography, Kits precoated with the antibody to each hormone purchased from Mesoscale Discovery, OLINK, Shotgun Metagenomic DNA Sequencing, Specific gravity corrected concentrations (nanograms/ml) of phthalate ester metabolites, Targeted liquid chromatography with tandem mass spectrometry (LC-MS/MS) assays, Targeted nuclear magnetic resonance (NMR) | Genome British Columbia, AllerGen Networks of Centres of Excellence, Canadian Institutes of Health Research (CIHR), Genome Canada |